2024 ATS Onsite Highlights - 29

INNOVATION THEATER
6:30-8 p.m.
Marriott Marquis - Marina Ballroom F/G
Sponsored by: PVI, PeerView Institute for
Medical Education
Supported by: An educational grant from Insmed
Stories Behind the Science in Non-Cystic Fibrosis
Bronchiectasis: Understanding Disease Burden,
Diagnosing Early, and Looking Toward New
Management Options
Although early diagnosis of NCFBE is of paramount importance,
misdiagnosis or delayed diagnosis are common due to
nonspecific symptoms and overlap with other conditions.
Insights into the pathophysiology of NCFBE have led to
development of novel and emerging agents to address
underlying inflammation.
PeerView has prepared an educational event that will
review the disease burden, strategies for diagnosis, disease
progression, and novel/emerging therapies in NCFBE.
Speakers: Cedric " Jamie " Rutland, MD, CEO and medical director,
Rutland Medical Group; and Doreen Addrizzo-Harris, MD,
professor of medicine, NYU School of Medicine
6:30-9:30 p.m.
Manchester Grand Hyatt - Grand Hall
Sponsored by: Merck & Co., Inc.
A Recent Development for Adults with Pulmonary
Arterial Hypertension
Learning Objectives:
1. Define pulmonary arterial hypertension
2. Provide an overview of a treatment option for appropriate
adults with PAH
3. Review the dosing and administration of a treatment
option for appropriate adults with PAH
Speaker: TBA
INNOVATION HUB EVENING SYMPOSIA
6:30-9:30 p.m.
Hilton Bayfront - Sapphire Ballroom
Sponsored by: Genentech
Approaches to COPD care: Targeting the ST2 receptor
and IL-33 pathway as a potential option for patients
at risk of exacerbating
This educational event presents the latest scientific
thinking in COPD care. Gain knowledge through educational
presentations that bring to life:
* The COPD patient: immunology, pathophysiology, and
psychological burden
* Astegolimab,* an investigational monoclonal antibody,
potentially targeting the ST2 receptor and IL-33 pathway
* The Genentech and Roche commitment to diversity
in research
*Astegolimab and its uses are investigational and have not been approved
by the US Food and Drug Administration.
Speakers: Monica Kraft, MD, the Murray M. Rosenberg
Professor of Medicine and System Chair, Department of
Medicine at Mount Sinai Health System and the Icahn School
of Medicine at Mount Sinai; and Nicola Hanania, MD, MS,
FERS, FRCPC, FCCP, Harris Health System - Ben Taub Hospital
(Pulmonary, Critical Care, and Sleep Medicine)
6:30-9:30 p.m.
Hilton Bayfront - Indigo Ballroom
Sponsored by: Amgen/AstraZeneca
Epithelial Cytokines: Connecting the Dots in Severe
Asthma, Nasal Polyps, and COPD
Amgen and AstraZeneca invite you to this expert-led
presentation discussing the role of epithelial cytokines as
primary drivers of airway disease. Our panel will discuss severe
asthma, chronic rhinosinusitis with nasal polyps, and COPD,
providing important insights on the contribution of epithelial
cytokines to disease pathophysiology and epithelial-driven
inflammation. At the end of the program, attendees will have
a greater appreciation of the evolving science of epithelial
cytokines and a different perspective on the patients they see
in clinical practice.
Speakers: Rohit Katial, MD, National Jewish Health; Andrew
White, MD, Scripps Clinic; and Igor Barjaktarevic, MD, PhD,
University of California, Los Angeles
Onsite Highlights | San Diego
29
SUNDAY, MAY 19
2024 ATS Onsite Highlights

Table of Contents for the Digital Edition of 2024 ATS Onsite Highlights
